GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction

Guidelines currently recommend organ-specific management of obesity-related complications. Agents that agonize glucagon-like peptide 1 receptors, including those that co-agonize other anorexigenic hormone receptors, lead to substantial weight loss and benefits in people with varying obesity-related complications, with further trials underway. These medications enable cause-specific management of obesity complications.